Gene-editing firm Seamless Therapeutics has attracted its first major pharma partner, Eli Lilly, with a $1.12bn alliance focused on hearing loss.
Takeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says
Takeda’s incoming CEO took a firm stance against President Donald Trump’s “most favored nation” deals with drugmakers on Thursday, while Sanofi and Roche shared new



